Tumor mutation burden as a marker for molecularly matched therapy: more evidence needed

被引：0
|
作者：
Meng, Xiang-Yu [1 ,2 ]
Wu, Qiu-Ji [3 ]
机构：
[1] Hubei Minzu Univ, Hlth Sci Ctr, Enshi 445000, Peoples R China
[2] Hubei Minzu Univ, Hubei Prov Key Lab Occurrence & Intervent Rheumat, Enshi 445000, Peoples R China
[3] Wuhan Univ, Zhongnan Hosp, Hubei Canc Clin Study Ctr, Dept Radiat & Med Oncol,Hubei Key Lab Tumour Biol, Wuhan 430071, Peoples R China
来源：
EPIGENOMICS | 2023年 / 15卷 / 22期
关键词：
biomarker; molecularly matched therapy; prognosis; targeted therapy; tumor mutation burden;
D O I：
10.2217/epi-2023-0354
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
引用
收藏
页码：1175 / 1178
页数：4
相关论文
共 50 条
  • [31] The Impact of Current Smoking Status at Initiation of Immune Checkpoint Inhibitor Therapy on Tumor Mutation Burden and Survival
    Wu, J. T.
    La, J.
    Han, S.
    Das, M.
    Glover, M.
    Scobie, M.
    Brophy, M.
    Do, N.
    Ahmed, S.
    Fillmore, N.
    Kelley, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S359 - S360
  • [32] Peritoneal seeding is more common in gastric cancer patients with FGFR2 amplification or high tumor mutation burden
    Kim, Hyunjin
    Ahn, Soomin
    Kim, Kyoung-Mee
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 481 - 481
  • [33] Peritoneal seeding is more common in gastric cancer patients with FGFR2 amplification or high tumor mutation burden
    Kim, Hyunjin
    Ahn, Soomin
    Kim, Kyoung-Mee
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 481 - 481
  • [34] Peritoneal Seeding Is More Common in Gastric Cancer Patients with FGFR2 Amplification or High Tumor Mutation Burden
    Kim, Hyunjin
    Park, Sujin
    Kang, So Young
    Ahn, Soomin
    Kim, Kyoung-Mee
    DIAGNOSTICS, 2022, 12 (10)
  • [35] Peritoneal seeding is more common in gastric cancer patients with FGFR2 amplification or high tumor mutation burden
    Kim, Hyunjin
    Ahn, Soomin
    Kim, Kyoung-Mee
    MODERN PATHOLOGY, 2022, 35 : 481 - 481
  • [36] More evidence is needed on the additional efficacy of vedolizumab as a first-line biologic therapy for inflammatory bowel disease
    Kakiuchi, Toshihiko
    Yoshiura, Masato
    DIGESTIVE AND LIVER DISEASE, 2023, 55 (02) : 298 - 299
  • [37] Microsatellite instability and tumor mutation burden as factors in ovarian clear-cell carcinoma therapy selection.
    Takamatsu, Shiro
    Matsumura, Noriomi
    Brown, J. B.
    Itamochi, Hiroaki
    Hamanishi, Junzo
    Yamaguchi, Ken
    Sugiyama, Toru
    Baba, Tsukasa
    Mandai, Masaki
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 51 - 52
  • [38] Prioritization of Therapy Options for a Patient With High Tumor Mutation Burden and Microsatellite Instability but No Clinical Benefit From Immunotherapy
    Nelson, Ryan S.
    Mehta, Rutika J.
    McLeod, Howard L.
    Walko, Christine M.
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 7
  • [39] Tumor Mutation Burden Correlates With Efficacy of Chemotherapy/Targeted Therapy in Advanced Non-Small Cell Lung Cancer
    Lin, Chen
    Shi, Xun
    Zhao, Jun
    He, Qiong
    Fan, Yun
    Xu, Weizhen
    Shao, Yang
    Yu, Xinmin
    Jin, Ying
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [40] Molecular tumor board: molecularly adjusted therapy upon identification and functional validation of a novel ALK resistance mutation in a case of lung adenocarcinoma
    Arndt, Annette
    Neumann, Christian
    Riecke, Armin
    Bauer, Arthur
    Mueller, Matthias
    Woelfle-Guter, Manuela
    Grunert, Michael
    Busch, Hauke
    Kuenstner, Axel
    von Bubnoff, Nikolas
    Fliedner, Stephanie
    Greinert, Dina
    Osius, Jasmin
    Nagarathinam, Kumar
    Steinestel, Konrad
    Gorantla, Sivahari Prasad
    Gebauer, Niklas
    Witte, Hanno M.
    ONCOLOGIST, 2024, 30 (01):
12345